• Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments

    1 month ago - By Xconomy

    Privately held biotech ViaCyte has banked $27 million, the majority an installment of cash from a tranched $80 million Series D financing round it closed in late 2018. The company says the money will go to further develop the three diabetes treatment programs it has underway, including enough prep work to enable it to bring the latest addition to its pipeline, which uses gene-editing, into clinical trials. ViaCyte is a regenerative stem cell company that is pursuing a trio of avenues to help people with diabetes who require insulin to supplement what their body produces. If all goes...
    Read more ...